Status message

Not the entire site translated, but only to "Journal"

HEALTH OF PATIENTS WITH SERIOUS MENTAL ILLNESS DURING COVID: FOCUS ON SCHIZOPHRENIA

N. N. Petrova 
Saint-Petersburg State University, department of psychiatry and narcology, Saint-Petersburg, Russia
SUMMARY
The consequences of the pandemic for persons with serious mental illnesses, particularly schizophrenia, pose a pressing challenge to psychiatric science and practice. COVID-19 has had an unprecedented impact on populations worldwide and places a heavy burden on patients with schizophrenia, including increased risk of infection and poor outcomes, adverse effects on the mental health of patients with schizophrenia, and difficulties in organizing psychiatric care for these patients in inpatient and outpatient settings. The recommendations emphasize the importance of rapidly implementing measures to both reduce the risk of COVID-19 transmission and to maintain continuity of psychiatric care for patients with schizophrenia.

CONTACT: Natalia Petrova, petrova_nn@mail.ru
http://orcid.org/0000-0003-4096-6208
CITATION: Petrova N.N. Health of Patients with Serious Mental Illness During COVID-19: Focus on Schizophrenia // Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders]. – 2021. – No. 1. – P. 8–13. – DOI: 10.21265/PSYPH.2021.87.48.002 [in Russian]
Conflict of interest: non declared.
 

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1.    Coronavirus disease (COVID-19) outbreak. WHO characterizes COVID-19 as a pandemic. World Health Organization website. https://who.int/emergencies/diseases/novel-coronavirus-2019/events-as-th.... March 11, 2020.
2.    Coronavirus Worldometer. Worldometer website. https://www.worldometers.info/coronavirus/. Accessed April 16, 2020.
3.    Lai J., Ma S., Wang Y et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019// JAMA Network Open.-2020.- Vol. 3(3).- e203976. doi:10.1001/jamanetworkopen.2020.3976 
4.    Anmella G., Fico G.,  Roca A. et al. Unravelling potential severe psychiatric repercussions on healthcare professionals during the COVID-19 crisis// J Affect Disord.- 2020.- Vol. 273. - P. 422–424. doi: 10.1016/j.jad.2020.05.061
5.    Bo H.X., Li W., Yang Y. et al. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China// Psychological Medicine. – 2020. - 1 - P. 1 – 2. DOI: https://doi.org/10.1017/S0033291720000999
6.    Tso I.F., Grove T.B., Taylor S.F. Self-assessment of psychological stress in schizophrenia: Preliminary evidence of reliability and validity// Psychiatry Research. - 2012.- Vol. 195(1–2). – Р. 39–44. doi: 10.1016/j.psychres.2011. 07.009  
7.    Brooks  S.K., Webster  R.K., Smith  L.E. et al.  The psychological impact of quarantine and how to reduce it: rapid review of the evidence// Lancet. – 2020. – Vol. 395(10227). -  P. 912-920. doi:10.1016/S0140-6736(20)30460-8
8.    Li S., Zhang Y. Mental healthcare for psychiatric inpatients during the COVID-19 epidemic// Gen. Psychiatr. -2020. – Vol. 33.- e100216. https://doi.org/10.1136/gpsych-2020-100216.
9.    Druss  B.G.  Addressing the COVID-19 pandemic in populations with serious mental illness// JAMA Psychiatry. - 2020.- Published online. doi:10.1001/jamapsychiatry.2020.0894
10.    Zhand N., Joober R. Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review// B J Psych Open.- 2021. – Vol. 7, №1. - e35 doi: 10.1192/bjo.2020.157.
11.    Basrak N., Mulcrone N., Sharifuddin S. et al. Risk of adverse outcome of COVID-19 among patients in secure psychiatric services: observational cohort study//B J Psych Open. – 2021.- Vol. 7, №1. - e31 DOI: https://doi.org/10.1192/bjo.2020.169
12.    Kozloff N.,  Mulsant B.H., Stergiopoulos V.,  Voineskos A.N. The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders// Schizophr Bull. – 2020. – Vol. 46(4). – P. 752-757. doi: 10.1093/schbul/sbaa051.
13.    Xiang Y.-T., Yang Y., Li W. et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed//The Lancet Psychiatry.- 2020.- Vol. 7(3). P. 228–229. https://doi.org/10.1016/s2215-0366(20)30046-8 
14. Barber S., Reed L., Syam N., Jones N. Severe mental illness and risks from COVID-19. On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford.  www.cebm.net 
15.    Iasevoli F., Fornaro M., D’Urso G. et al. Psychological distress in patients with serious mental illness during the COVID-19 outbreak and one-month mass quarantine in Italy//Psychological Medicine. – 2020. - First ViewFirst View. – P. 1–3. https://doi.org/10.1017/S0033291720001841
16.    Liu X., Lin H., Jiang H. et al. Clinical characteristics of hospitalised patients with schizophrenia who were suspected to have coronavirus disease (COVID-19) in Hubei Province, China // General Psychiatry. – 2020. – Vol. 33(2). - e100222. https://doi.org/10.1136/gpsych-2020-100222
17.    Yao H., Chen J.H., Xu Y.F. Patients with mental health disorders in the COVID-19 epidemic// Lancet Psychiatry. – 2020. – Vol. 7(4). - e21. doi: 10.1016/S2215-0366(20)30090-0. PMID: 32199510;PMCID: PMC7269717.
18.    Sheffield J.M., Karcher N.R., Barch D.M. Cognitive deficits in psychotic disorders: a lifespan perspective // Neuropsychol Rev. – 2018. – Vol. 28(4). – P. 509–533.
19.    Dickerson F., Stallings C.R., Origoni A.E. et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999–2011//Psychiatr Serv. – 2013. – Vol. 64(1). – P. 44–50.
20.    Leung J.M., Yang C.X., Tam A. et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 [published online ahead of print April 8, 2020]// Eur Respir J.
21.    Folsom D.P., Hawthorne W., Lindamer L. et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system// Am J Psychiatry. – 2005. –Vol. 162(2). – P. 370–376.
22.    McGinty E.E., Baller J., Azrin S.T. et al. Quality of medical care for persons with serious mental illness: a comprehensive review// Schizophr Res. – 2015. – Vol. 165(2–3). P. 227–235.
23.    Kim M.J. How a South Korean psychiatric ward became a “medical disaster” when coronavirus hit// Washington Post. - 2020. https://www.washingtonpost.com/world/asia_pacific/how-a-south-korean-psy...
24.    Morrissette M., Shamlou A. Experiences of treating patients with psychotic symptoms during the COVID-19 pandemic// Psychosis. – 2020. -  DOI:10.1080/17522439.2020.1769165
25.    Lee S.W., Yang J.M., Moon S.Y. et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study// Lancet Psychiatry. -  2020.- Vol. 7, №12.- P. 1025-1031.
26.    Guan W.J., Ni Z.Y., Hu Y. et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China // N Engl J Med. – 2020. – Vol. 382. – P. 1708-1720. DOI: 10.1056/NEJMoa2002032
27.    Olfson M., Gerhard T., Huang C. et al. Premature mortality among adults with schizophrenia in the United States// JAMA Psychiatry. – 2015. – Vol. 72(12). P. 1172–1181.
28.    Сhou F.H., Tsai K.Y., Chou Y.M. The incidence and all-cause mortality of pneumonia in patients with schizophrenia: a nine-year follow-up study// J Psychiatr Res. – 2013. – Vol. 47(4). - P. 460–466.
29.    Haga T., Ito K., Sakashita K. et al. Risk factors for pneumonia in patients with schizophrenia// Neuropsychopharmacol Rep. – 2018. – Vol. 38(4). – P. 204–209. 
30.    Dzahini O., Singh N., Taylor D. et al. Antipsychotic drug use and pneumonia: systematic review and meta-analysis// J Psychopharmacol. – 2018. – Vol. 32(11). P. 1167–1181.
31.    Fonseca L., Diniz E., Mendonc¸a G. et al. Schizophrenia and COVID‐19: risks and recommendations// Braz J Psychiatry. – 2020. – Vol. 42. – P. 236‐238. http://dx.doi.org/10.1590/1516‐4446‐2020‐0010
32.    Miller В. Health Disparities in Patients With Schizophrenia and COVID-19// Psychiatric Times. 2020. www.psychiatrictimes.com
33.    Stubbs B., Thompson T., Acaster S. et al. Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies// Pain. – 2015. – Vol. 156(11). – P. 2121–2131.  
34.    Nemani K., Li C., Olfson M. et al. Association of Psychiatric Disorders With Mortality Among Patients With COVID-19//JAMA Psychiatry. – 2021.e204442. doi: 10.1001/jamapsychiatry.2020.4442.
35.    Zeng L., Zhang H.,  He Y. et al. Case report. A severe COVID-19 case with schizophrenia as well as other chronic diseases// Braz J Med Biol Res. – 2021. - Vol.54, №3. http://dx.doi.org/10.1590/1414-431x202010426  
36.    Cranshaw Т., Harikumar Т. COVID‐19 Infection May Cause Clozapine Intoxication: Case Report and Discussion// Schizophrenia Bulletin. – 2020. – Vol. 46(4). – P. 751. doi: 10.1093/schbul/sbaa070 
37.    Mosolov S.N. Aktual'nye zadachi psihiatricheskoj sluzhby v svyazi s pandemiej COVIDE19 // Sovremennaya terapiya psihicheskih rasstrojstv. – 2020. – № 2. DOI: 10.21265/PSYPH.2020.53.59536
38.    38.    Mosolov SN. Problemy psihicheskogo zdorov'ya v usloviyah pandemii COVID-19 // ZHurnal nevrologii i psihiatrii im. S. S. Korsakova. – 2020. – Vol. 120(5). P. 7-15. DOI: 10.17116/jnevro20201200517.
39.    https://www.covid19‐druginteractions.org Информация о взаимодействии противовирусных лекарств с психотропными и другими препаратами с сайта отделения клинической фармакологии Ливерпульского университета. Адаптировано С. Н. Мосоловым для РФ в 2020 г. Доступ проверен 18.11.2020 г.
40.    Hansen D.H., Baandrup L., Hageman I.  COVID‐19 Associated Severe Psychotic Relapse// Ugeskrift for laeger.- 2020. – Vol. 182(24).- V05200354.
41.     Kahl K.G.,  Correll C.U.  Management of Patients With Severe Mental Illness During the Coronavirus Disease 2019 Pandemic//JAMA Psychiatry. – 2020. – Vol. 77(9). – P. 977-978. doi:10.1001/jamapsychiatry.2020.1701
42.    Brown Е., Gray R, Lo Monaco S. et al. The potential impact of COVID-19 on psychosis: A rapid review of contemporary epidemic and pandemic research//Schizophrenia Research. – 2020. - Vol. 222.- P. 79-87. https://doi.org/10.1016/j.schres.2020.05.005
43.    Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency: Guidance for Industry and Healthcare Professionals. US Food & Drug Administration website. https://www.fda.gov/media/136317/download. March 2020.
44.    Shinn A.K., Viron M.  Perspectives on the COVID-19 Pandemic and Individuals With Serious Mental Illness// J Clin Psychiatry. – 2020. – Vol. 81(3). 20com13412. doi: 10.4088/JCP.20com13412.
45.    Henson Р.,  D’Mello R., Vaidyam А.  et al. Anomaly detection to predict relapse risk in Schizophrenia. Translational Psychiatry (2021) 11:28. https://doi.org/10.1038/s41398-020-01123-7
46.    Szmulewicz A.G., Benson N.M., Hsu J. et al. Effects of COVID-19 pandemic on mental health outcomes in a cohort of early psychosis patients// Early Intervention in Psychiatry. – 2021. – P. 1–4. https://doi.org/10.1111/eip.13113
47.    Correll C.U., Lauriello J. Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia // J Clin Psychiatry.- 2020.- Vol. 81, №4. MS19053AH5C https://doi.org/10.4088/JCP.MS19053AH5C
48.    Huhn М., Nikolakopoulou А., Schneider-Thoma J.  Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis// Lancet. – 2019. – Vol. 394. - P. 939–51. 
49.    Ifteni Р., Dima L., Teodorescu F. Long-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge// Schizophrenia Res. -  2020. – Vol. 220. –P. 265–266.
50.    Siskind D., Northwood K., Berk M. et al.  Monitoring for postinjection delirium/sedation syndrome with long‐acting olanzapine during the COVID‐19 pandemic// Aust N Z J Psychiatry. – 2020. – Vol. 54(7). – P. 759-761. doi: 10.1177/0004867420927465. Epub 2020 May 14
51.    Gannon J.M., Conlogue J., Sherwood R. Long acting injectable antipsychotic: Ensuring care continuity during the COVID-19 pandemic restrictions// Schizophrenia Res. -2020. – Vol. 222. – P. 532–533. https://doi.org/10.1016/j.schres.2020.05.001
52.    Greene M., Yan T. , Chang E. et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder// J Med Econ. – 2018. – Vol. 21(2). - P. 127-134. doi: 10.1080/13696998.2017.1379412.
53.    Recommendations for Mental Health Departments regarding activities and measures of contrast and containment of the SARS-COV-19 virus//J Italian Soc Psych. Evidence-based Psychiatric Care. - 2020. www.evidence-based-psychiatric-care.org 
54.    Figueroa C.A., Aguilera A. The Need for a Mental Health Technology Revolution in the COVID-19 Pandemic// Front Psychiatry. -2020. – Vol. 11. –P. 523. DOI: 10.3389/fpsyt.2020.00523.
55.    Rentero D., Juanes A., Losada С.P. et al. New-onset psychosis in COVID-19 pandemic: a case series in Madrid // Psychiatry Research.- 2020. – Vol. 290. doi: 10.1016/j.psychres.2020.113097
56.    Zandifar А., Badrfam R. COVID-19: Considering the prevalence of schizophrenia in the coming decades // Psychiatry Res. – 2020. – Vol. 288. – P. 112982.
57.    Hu W., Su L., Qiao J., Zhu J., Zhou Y. COVID-19 outbreak increased risk of schizophrenia in aged adults. - 2020. - Chinaxiv.org (preprint)
58.    Yesilkaya U.H., Balcioglu Y.H., Sahin S. Reissuing the sigma receptors for SARS-CoV-2// J Clin Neurosci. – 2020. – Vol. 80. – P. 72-73. DOI: 10.1016/j.jocn.2020.08.014.
59.    Crunfli F., Carregari V.С., Veras F.P. et al. SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability. doi: https://doi.org/10.1101/2020.10.09.20207464
 

Яндекс.Метрика